“GLP-1受体激动剂(GLP-1RA)这一类药物,能够在控制血糖、降低体重、保护心血管、改善新陈代谢、保护肝脏和肾脏方面等多个领域发挥积极有效的作用。诺和忻®的突破在于能够使GLP-1RA类药物以口服形式用药。”近日,诺和诺德公司法规质量和临床报告高级副总裁Mads Frederik Rasmussen在诺和忻® (司美格鲁肽片)中国上市之际介绍称,相比传统的注射方式,诺和忻®便捷的给药方式和被...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.